Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Foretinib · 4 trials · 4 indications
All patients will be assessed for response at the end of every second cycle (every 8 weeks). Response and progression will be evaluated using RECIST 1.1.
Overall response rate is the percentage of participants for whom the best overall response to the study drug was a confirmed partial response (PR) or confirmed complete response (CR). Best overall response and its associated confirmation criteria, RECIST; Version 1.0) was based on the Investigator's assessment of the target and non target lesions.
Adverse events will be graded using CTCAE V4.0
| Arm | Type | Description |
|---|---|---|
| Foretinib | EXPERIMENTAL | - |
| 5/9 dosing | EXPERIMENTAL | 240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days. |
| daily dosing | EXPERIMENTAL | 80 mg foretinib on a daily dosing regimen |
| Foretinib and Lapatinib | EXPERIMENTAL | Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1. |
| Name | Type | Description |
|---|---|---|
| Foretinib | DRUG | foretinib, at a continuous oral daily dose of 60 mg |
| foretinib (formerly GSK1363089 or XL880) | DRUG | treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule |
| Lapatinib | DRUG | Daily oral dosing at assigned dose beginning day 1 cycle 1. |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of invasive breast cancer, that is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. * Formalin fixed paraffin embedded tissue available for cen...
Top 20 of 92 competitors
Foretinib is an investigational small molecule being studied for the treatment of several cancers, including recurrent breast cancer, breast cancer, renal cell carcinoma, and hepatocellular carcinoma. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved.
Foretinib is being developed by GSK plc, which trades under the ticker GSK. The company has sponsored clinical trials of the drug across multiple cancer types, including renal cell carcinoma, hepatocellular carcinoma, and breast cancer.
Foretinib has been studied in Phase 1 and Phase 2 clinical trials. Its development program includes completed Phase 1 studies in liver cancer and breast cancer, as well as Phase 2 studies in renal cell carcinoma and recurrent breast cancer. It is investigational and not approved.
Foretinib has been evaluated in several completed trials, including NCT00726323 for papillary renal-cell carcinoma, NCT00920192 for liver cancer, NCT01138384 for metastatic breast cancer in combination with lapatinib, and NCT01147484 for recurrent or metastatic breast cancer.
Yes, Foretinib is also known as GSK1363089, formerly XL880. Clinical trial records refer to the drug by both names, such as in the Phase 2 study of GSK1363089 for papillary renal-cell carcinoma.